Analysts Offer Insights on Healthcare Companies: Candel Therapeutics (CADL) and Stereotaxis (STXS)
Analysts have been eager to weigh in on the Healthcare sector with new ratings on Candel Therapeutics (CADL – Research Report) and Stereotaxis (STXS – Research Report).
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Candel Therapeutics (CADL)
In a report released today, Alec Stranahan from Bank of America Securities maintained a Hold rating on Candel Therapeutics. The company’s shares closed last Tuesday at $5.45.
According to TipRanks.com, Stranahan is a 4-star analyst with an average return of
Candel Therapeutics has an analyst consensus of Strong Buy, with a price target consensus of $20.60, a 290.9% upside from current levels. In a report issued on December 30, TipRanks – OpenAI also upgraded the stock to Hold with a $6.00 price target.
See today’s best-performing stocks on TipRanks >>
Stereotaxis (STXS)
According to TipRanks.com, Jennings is a 3-star analyst with an average return of
Stereotaxis has an analyst consensus of Strong Buy, with a price target consensus of $4.20, which is a 57.9% upside from current levels. In a report released today, Lake Street also maintained a Buy rating on the stock with a $4.00 price target.
